On the stock market since 2024, it operates in the world of heavy industry. It has 9,400 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 16% a year over the last 4 years. Every year shown ended in profit.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
The stock has been running stronger than the market lately.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 21% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 12% a year on average.
It met or beat analyst expectations in 6 of the last 7 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 19 buys and 12 sells. Management buying with its own money is usually read as a good sign.
This stock swings about 2.3 times as much as the market average. Big rallies — and big drops — can both happen fast.
The company’s market value is 34 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, ECG sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ECG is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.